CTRI/2019/07/020067进行中（未招募）4 期
A Cross-sectional, Multicenter, Epidemiological Study to Determine the Sociodemographic and Clinical Profiles of Patients With Irritable Bowel Syndrome (IBS) in India
Abbott Healthcare India Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Male or female patients aged >= 18 years
- •2. Patients diagnosed with IBS in last 1 month as per the Asian criteria
- •3. Patients who are willing to participate in the study and competent to sign a patient authorization form (PAF) for participation in the registry
排除标准
- •1. IBS patients with evidence of structural abnormality in the GI tract or diseases/conditions that may affect bowel transit
- •2. IBS patients with evidence of acute GI conditions like obstructions, bleeding, and perforation, or GI surgery
- •3. IBS patients with evidence of severe systemic disorders (cardiac, hepatic, neurological, or renal)
- •4. Pregnant or lactating patients
- •5. Any condition that in the opinion of the investigator does not justify the patientâ??s inclusion in the study
研究者
相似试验
已完成
不适用
An epidemiological study to estimate the burden of respiratory syncytial virus (RSV) infection in adults aged >- 60 years with acute respiratory infection (ARI), in Japan.Acute Respiratory Infection / RS Virus InfectionJPRN-jRCT1030210195Katsumata Masayuki3,000
招募中
不适用
To aim of this study is to determine the prevalence of Non-Alcoholic Fatty Liver Disease and Thyroid Dysfunction in Patients with Metabolic Syndrome.CTRI/2016/09/007270Abbott India Limited400
已完成
不适用
This study is to understand the Clinical Characters, Social & demographic Profile, and Treatment Patterns in Patients with Bipolar Depression in IndiaCTRI/2018/09/015861Abbott Healthcare Pvt Ltd574
尚未招募
不适用
Study to characterize the efficacy and performance of the 100% Silicone Foley Balloon Catheter 2-wayCTRI/2024/01/061801Sterimed Group
招募中
Unknown
A study to see the prevalence of HER2 low, clinical characteristics, treatment patterns, and outcomes in patients with HER2 negative locally advanced or metastatic breast cancer who progressed on systemic anticancer therapy.CTRI/2024/03/063553AstraZeneca Pharma India Ltd